Research Advisory Panel
California law, pursuant to Health & Safety Code Sections §11480 & §11481, requires proposed research projects using certain opioid, stimulant, and hallucinogenic drugs classified as Schedule I and Schedule II Controlled Substances as their main study drug(s), to be reviewed and authorized by the Research Advisory Panel of California in the Attorney General's Office. See the Guidelines page for specific criteria.
The Research Advisory Panel primarily seeks to ensure the safety and protection of participating human research subjects and adequate security of the controlled substances used in the study. The Panel Members evaluate the scientific validity of each proposed project, and may reject proposals where the research is poorly conceived, would produce conclusions of little scientific value, or would not justify the exposure of California subjects to the risk of research.
During 2016 the Panel reviewed thirty-five research study submissions. Thirty-two were approved by the Panel. Among the approved studies, nineteen studies were Academic research studies, thirteen studies were Multi-Center Clinical Drug Trial research studies.
At the end of 2016, the Panel was monitoring one hundred and eleven research projects.
The Research Advisory Panel does NOT have any information about a State or DEA registration license for the scheduled drugs, applicants may inquire the DEA website at www.deadiversion.usdoj.gov for the DEA registration/license.
Applicants may utilize the DEA Controlled Substance Listings link for further information on controlled substance schedules.